We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
- Authors
Zuo, Ke; Qi, Yingying; Yuan, Cai; Jiang, Longguang; Xu, Peng; Hu, Jianping; Huang, Mingdong; Li, Jinyu
- Abstract
Matriptase is a type II transmembrane serine protease, which has been suggested to play critical roles in numerous pathways of biological developments. Matriptase is the activator of several oncogenic proteins, including urokinase-type plasminogen activator (uPA), hepatocyte growth factor (HGF) and protease-activated receptor 2 (PAR-2). The activations of these matriptase substrates subsequently lead to the generation of plasmin, matrix metalloproteases (MMPs), and the triggers for many other signaling pathways related to cancer proliferation and metastasis. Accordingly, matriptase is considered an emerging target for the treatments of cancer. Thus far, inhibitors of matriptase have been developed as potential anti-cancer agents, which include small-molecule inhibitors, peptide-based inhibitors, and monoclonal antibodies. This review covers established literature to summarize the chemical and biochemical aspects, especially the inhibitory mechanisms and structure-activity relationships (SARs) of matriptase inhibitors with the goal of proposing the strategies for their future developments in anti-cancer therapy.
- Subjects
ONCOGENIC proteins; METASTASIS; HEPATOCYTE growth factor; PLASMINOGEN activators; PROTEASE-activated receptors
- Publication
Cancer & Metastasis Reviews, 2019, Vol 38, Issue 3, p507
- ISSN
0167-7659
- Publication type
Article
- DOI
10.1007/s10555-019-09802-8